CBU
HRTX icon

CIBC Bancorp USA’s Heron Therapeutics HRTX Stock Holding History

CIBC Bancorp USA’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$20.5K Buy
+16,307
New +$25.9K ﹤0.01% 1453

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIBC Bancorp USA's HRTX Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Heron Therapeutics (HRTX) in Q3 2025: 16,307 shares worth $20.5K. The stake represents ﹤0.01% of the portfolio and ranks #1453 among its holdings.

172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • CIBC Bancorp USA held 16,307 shares of Heron Therapeutics worth $20.5K as of Q3 2025.
  • Heron Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Heron Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1453 holding.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.